SCHEDULE: Veradace Opposes Tiptree's Fortegra Sale, Citing Undervaluation

Veradace Partners, a significant Tiptree shareholder, has filed an amended Schedule 13D to detail its strong opposition to the proposed sale of Fortegra to DB Insurance, citing undervaluation and a flawed process.

Summary

• Veradace Partners L.P. and its affiliates, holding 5.1% of Tiptree Inc.'s outstanding common stock, are actively opposing the proposed sale of The Fortegra Group, Inc. to DB Insurance Co., Ltd.
• Veradace issued a press release and presentation on November 13, 2025, urging shareholders to vote AGAINST the transaction at the Special Meeting scheduled for December 3, 2025.
• The opposition is based on claims of Fortegra's undervaluation, a flawed and conflicted process, and a tax-inefficient structure that provides no direct return to Tiptree shareholders.
• Veradace submitted a letter to the SEC on November 16, 2025, raising concerns about material omissions in Tiptree's definitive proxy statement regarding the Fortegra transaction.
• Key omissions cited include Veradace's prior offers to backstop a Fortegra IPO with $50-75 million, valuation ranges for prior attempted IPOs, selective omission of non-GAAP adjusted net income, details on change in control benefits for Tiptree executive officers, and risks related to the Investment Company Act of 1940 post-transaction.
• Veradace believes the transaction is priced at a significant discount to comparable companies on a multiple of net income, with the proxy statement showing a 10.7x GAAP net income multiple, while a non-GAAP adjusted net income would imply a lower 9.8x multiple.
• The aggregate purchase price of the securities reported by Veradace was approximately $14,520,758, funded from working capital, with some positions held in margin accounts.

Sentiment

Score: 2

Explanation: The filing expresses strong negative sentiment regarding the proposed transaction, detailing numerous perceived flaws, undervaluation, and potential harm to shareholders. It is an activist investor's direct opposition to a company's strategic move.

Positives

• Veradace Partners is actively advocating for what it believes are superior alternative paths to deliver materially higher, tax-efficient returns to shareholders, including a restructured deal.

Negatives

• The proposed sale of Fortegra is deemed deeply flawed and undervalues the asset, according to Veradace Partners.
• The transaction process is described as flawed and conflicted, with a tax-inefficient structure that grants management a 'blank check' while delivering no direct return to shareholders.
• The transaction is priced at a significant discount to comparable companies on a multiple of net income (10.7x GAAP vs. 9.8x implied non-GAAP adjusted net income).
• Tiptree's proxy statement is alleged to omit material facts, including Veradace's offers to backstop a Fortegra IPO, prior IPO valuation ranges, and details on executive change in control benefits.
• Concerns are raised about Tiptree potentially facing regulation under the Investment Company Act of 1940 after the transaction, given that nearly 100% of its assets would consist of cash and de minimis investments.

Risks

• Tiptree may face regulation under the Investment Company Act of 1940 after the transaction, as nearly 100% of its assets would consist of cash and de minimis investments.
• Timeline pressures to avoid Investment Company Act regulation could be detrimental to shareholders.
• The proposed transaction, if approved, may result in a suboptimal valuation for Fortegra and Tiptree shareholders.
• The alleged material omissions in the proxy statement could prevent shareholders from making an informed voting decision.

Future Outlook

Veradace Partners believes there are numerous superior alternative paths that could deliver materially higher, tax-efficient returns to shareholders than the proposed Fortegra sale. They urge the Tiptree Board to pursue a restructured deal that maximizes shareholder value.

Management Comments

• Veradace questions why an investment bank was not retained to specifically sell Tiptree in a tax-efficient manner before or concurrently with pursuing a Fortegra sale.
• Veradace asks why the transaction was done now, months before Warburg Pincus LLC's Qualified Public Offering Rights and more than a year before Drag-Along Rights, given strong expected growth.
• Veradace questions how the Board evaluated a holding company discount in determining Fortegra's value and the transaction's value for Tiptree shareholders.
• Veradace asks why the proceeds from this transaction are not being returned, in whole, to shareholders.
• Veradace questions if independent directors believe the Proposed Transaction will be approved by a majority of unaffiliated shareholders, especially given affiliates own more than 40% of shares.

Industry Context

This filing represents a significant instance of shareholder activism, where a substantial investor is publicly challenging a major strategic transaction (asset sale) proposed by a company's board. It highlights common activist themes such as concerns over valuation, process integrity, corporate governance, and direct shareholder returns, particularly in the context of a holding company structure and potential post-transaction regulatory implications. The opposition to the Fortegra sale, a specialty insurance company, also touches upon the valuation dynamics within the insurance sector.

Comparison to Industry Standards

• Veradace contends the Fortegra transaction is priced at a significant discount to comparable companies on a multiple of net income, implying Tiptree is not achieving market-standard valuations for its asset.
• The filing implicitly compares the proposed sale to alternative exit strategies, such as an IPO, and questions the timing relative to Warburg Pincus LLC's Qualified Public Offering Rights and Drag-Along Rights, which are standard provisions in private equity investments.

Corporate Governance

Legal Proceedings

• Veradace Partners submitted a letter to the U.S. Securities and Exchange Commission (SEC) on November 16, 2025, raising concerns about material omissions in Tiptree's definitive proxy statement regarding the Fortegra Transaction. This could potentially lead to regulatory inquiry or action by the SEC.

Related Party Transactions

• The filing implies potential conflicts of interest by highlighting 'Change in Control Benefits to Tiptree Executive Officers,' where executive RSU awards accelerate and time-vesting requirements of stock options are waived upon a Change in Control, potentially valued at millions for certain officers.

Stakeholder Impact

• Shareholders: Potential negative impact if the proposed transaction proceeds as structured, due to alleged undervaluation, tax inefficiency, and no direct return of proceeds. Veradace is advocating for better shareholder value.
• Tiptree Management: Potential benefits from accelerated equity awards upon a Change in Control, which Veradace highlights as a concern.
• DB Insurance Co., Ltd.: The proposed buyer of Fortegra, whose acquisition is being actively opposed by a significant Tiptree shareholder, potentially jeopardizing the deal.
• Regulatory Authorities (SEC): Engaged by Veradace regarding alleged material omissions in Tiptree's proxy statement, potentially leading to increased scrutiny on Tiptree's disclosures and corporate governance.

Next Steps

• Shareholders are urged to vote AGAINST the proposed Fortegra transaction at Tiptree's Special Meeting of Stockholders on December 3, 2025.
• Veradace calls on the Tiptree Board to pursue a restructured deal that maximizes shareholder value.
• Veradace has shared its materials with proxy advisory firms and may continue discussions with them, shareholders, and others regarding the transaction.

Key Dates

Recommendation

The filing, from a significant activist shareholder, presents a compelling case that the proposed sale of Fortegra is deeply flawed, undervalues a core asset, and is structured to the detriment of Tiptree shareholders. It highlights serious corporate governance concerns, potential regulatory risks (Investment Company Act of 1940), and alleged material omissions in the company's disclosures. These factors collectively suggest a significant downside risk for Tiptree's stock if the transaction proceeds as planned, warranting a strong sell recommendation for investors seeking to avoid potential value destruction.

Keywords

Tiptree Inc., Fortegra Group, DB Insurance, Veradace Partners, Schedule 13D, shareholder activism, M&A, corporate governance, undervaluation, proxy statement, Investment Company Act of 1940